The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.

Slides:



Advertisements
Similar presentations
Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.
Advertisements

CINVForum Web-symposium dedicated to chemotherapy induced nausea and vomiting in lung cancer patients Survey on CINV – Results Base: 168 registered physicians.
Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by CapeOX plus BEV or single agent (s/a) BEV.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
The Nurse View: Management of Pancreatic Cancer
Evolving Paradigms in Recurrent/Metastatic SCCHN
The Nurse View.
Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
Perspectives on Triple-Negative Breast Cancer
Advanced NSCLC Without Actionable Mutations
The Nurse View.
Glaucoma Progression.
New Patient Journeys in Non-small cell lung cancer
Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.
The Nurse View.
Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.
Optimizing the Treatment of Recurrent/Metastatic SCCHN
The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.
Emerging Data in Cancer Supportive Care
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
Program Goals Introduction Case 1: A 44-Year-Old Woman.
Clinical Considerations in Evidence-based Management of GIST
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
Immunotherapy in Pancreatic Cancer: Thinking Outside the Box
Patient-Centric Approach to the Management of Spasticity
Updates in Preventing Skeletal-Related Events in Multiple Myeloma
Best Practices in Metastatic Colorectal Cancer
The Nurse View: Top Ten Things to Know About Immune-Mediated Adverse Events.
Treating mRCC After Initial Antiangiogenic Therapy:
Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.
The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.
Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer
From Symptom Management to Communication in Advanced GI Cancers
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Optimizing Outcomes and Managing Adverse Events in CLL
Baselga J et al. SABCS 2009;Abstract 45.
Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma
Patient-Centered Management in Pancreatic Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
Maintenance Therapy in Advanced Ovarian Cancer
The Road to Quality Improvement in HER2-Positive Breast Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
Extraordinary Cases in VTE
Treating Atypical Hemolytic Uremic Syndrome A Case Discussion
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
Program Goal. Program Goal Disclaimer Overview.
Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
AMD Therapy: Where Are We Now and Where Are We Going?
Clinical Considerations in Evidence-based Management of GIST
The Nurse View: Spotlight on EGFR-Mutated NSCLC
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
Patient and Clinician Perspectives on Preventive Therapy for Migraine
New Options for the Treatment of Hepatocellular Carcinoma
What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?
MSI.
Combining Immunotherapy and Chemotherapy in NSCLC
The Nurse View.
Understanding the Expanding Armamentarium for GIST
The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Recent Developments in the Treatment of Advanced and Metastatic RCC
Uncovering the Right Sequence
Presentation transcript:

The Nurse View: Updates in the Management of Metastatic Colorectal Cancer

Colorectal Cancer

Management of Patients With mCRC Overview

Case Study: Mr M Background

Case Study: Mr M Treatment History

Considerations for Second-Line Therapy in mCRC

Strategies for Communicating With and Educating Patients

Including Patients and Caregivers in Treatment Decisions

Second-Line Treatment Options for mCRC

Guidelines for Second-Line mCRC Treatment

Guidelines for Second-Line mCRC Treatment (cont)

Case Study: Mr. M (cont)

Managing Chemotherapy-Related Diarrhea

Prevention of Chemotherapy-Induced Peripheral Neuropathy

Management of Chemotherapy-Induced Peripheral Neuropathy

Anti-VEGF-Associated Hypertension

Bevacizumab-Related AEs

Case Study: Mr M (cont) Review of Case

Case Study: Mr M (cont)

NCCN mCRC Treatment Guideline Third-Line Treatment

Regorafenib Overview

Regorafenib Dosing and Administration

Regorafenib Adverse Events

Hand-Foot Syndrome vs Hand-Foot Skin Reaction

Preventing and Managing HFSR

Trifluridine-Tipiracil Overview

Trifluridine-Tipiracil Dosing and Administration

Trifluridine-Tipiracil Adverse Events

Nivolumab and Pembrolizumab Overview

Nivolumab and Pembrolizumab Adverse Events

Abbreviations

Abbreviations (cont)